Showing results (61-70 of 76) with videos related to
Sort By:
Pageof 8
The Oncologist|January 18, 2019
Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid SyndromeLowell B Anthony, Matthew H Kulke, Martyn E Caplin, et al.Endocrine-Related Cancer|January 9, 2016
Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension studyMartyn E Caplin, Marianne Pavel, Jarosław B Ćwikła, et al.The Lancet. Diabetes & Endocrinology|March 14, 2014
Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging studyEmanuel Christ, Damian Wild, Susanne Ederer, et al.European Journal of Cancer (Oxford, England : 1990)|January 22, 2014
Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumoursTim Meyer, Wendi Qian, Martyn E Caplin, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 22, 2025
[18F]FDG Metabolic Tumor Volume as a Prognostic Marker in Neuroendocrine Neoplasm: A Multicenter StudyDavid L Chan, Aimee Hayes, Ioannis Karfis, et al.Neuroendocrinology|September 20, 2020
Understanding the Treatment Algorithm of Patients with Metastatic Pancreatic Neuroendocrine Neoplasms: A Single-Institution Retrospective Analysis Comparing Outcomes of Chemotherapy, Molecular Targeted Therapy, and Peptide Receptor Radionuclide Therapy in 255 PatientsAimee R Hayes, Ingrid Y F Mak, Nicholas Evans, et al.Anti-Cancer Drugs|January 25, 2020
Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumorsTal Grenader, Marianne E Pavel, Philippe B Ruszniewski, et al.The Journal of Clinical Endocrinology and Metabolism|August 11, 2021
Metastatic Medullary Thyroid Cancer: The Role of 68Gallium-DOTA-Somatostatin Analogue PET/CT and Peptide Receptor Radionuclide TherapyAimee R Hayes, Alexander Crawford, Khulood Al Riyami, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 2, 2024
[18F]FDG PET/CT-Avid Discordant Volume as a Biomarker in Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter StudyDavid L Chan, Aimee R Hayes, Ioannis Karfis, et al.Current Oncology Reports|January 17, 2023
Where Are We Now with Liver Transplantation in Neuroendocrine Neoplasms? The Place of Liver Transplantation for Grades 1 and 2 Well-Differentiated Unresectable Liver Metastatic Neuroendocrine TumoursTahir Shah, Derek M Manas, Samuel J Ford, et al.Pageof 8